Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RARE
#2146
Ultragenyx Pharmaceutical Inc. - Common Stock
15.0
9
USD
+0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+1.14%
Monthly Change
+11.20%
6 month change
-39.03%
Year Change
-52.50%
Previous Close
14.9
2
Open
14.9
3
Low
14.6
7
High
15.1
8
Markets
US Stock Market
Healthcare
Biotechnology
RARE
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
66.95 M
69.38 M
70.22 M
82.34 M
92.5 M
96.63 M
98.59 M
Valuation ratios
Enterprise value
8.55 B
5.53 B
3.06 B
3.75 B
3.72 B
1.8 B
1.34 B
Price to earnings ratio
—
—
-4.5
-5.84
-6.69
-3.95
-2.55
Price to sales ratio
—
—
8.76
8.16
6.8
3.37
2.08
Price to cash flow ratio
—
—
-8.36
7.46
9.2
-4.87
-3.08
Price to book ratio
—
—
9.03
12.86
14.92
-28.35
-2.51
Enterprise value to EBITDA ratio
-26.91
-15.67
-5.08
-7.53
-8.77
-4.61
-3.59
Profitability ratios
Return on assets %
-0.11
-0.3
-0.46
-0.41
-0.38
-0.38
-0.07
Return on equity %
-0.16
-0.49
-2.01
-2.2
-2.23
7.19
0.32
Return on invested capital %
-318.35
-250.38
-378.82
-307.7
-275.6
-322.12
-41.07
Gross margin %
100
100
100
100
100
100
100
Operating margin %
-121.8
-108.63
-178.6
-131.08
-95.67
-79.49
-35.05
EBITDA margin %
-117.28
-100.4
-165.89
-114.73
-75.63
-58.1
-15.42
Net margin %
-68.84
-129.2
-194.71
-139.7
-101.6
-85.44
-42.99
Liquidity ratios
Quick ratio
6.76
4.63
3.28
2.49
2.24
2.34
1.56
Current ratio
6.83
4.72
3.38
2.61
2.37
2.48
1.73
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.19
0.21
0.24
0.29
0.37
0.44
0.17
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-5.44
-6.46
-4.57
-4.73
-4.84
EBIT per share
—
—
-8.88
-7.13
-5.07
-4.32
-4.07
EBITDA per share
—
—
-8.62
-6.77
-4.68
-3.97
-3.73
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
10.7
7.85
6.74
6.9
2.87
Net current asset value per share
—
—
12.64
9.96
9.03
9.65
5.95
Tangible book value per share
—
—
5.04
3.74
2.82
-3.04
-4.98
Working capital per share
—
—
8.91
6.14
5.22
5.75
2.5
Book value per share
—
—
5.04
3.74
2.82
-0.81
-2.86
News
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Stocks Finish Lower Ahead of Wednesday’s CPI Report
Binance to Lower Leverage and Margin Tiers for Multiple USDT-Margined Perpetual Contracts
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Stocks Settle Lower on Higher Bond Yields
Stocks Fall and Bond Yields Rise on Inflation Worries
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest